本文選題：左氧氟沙星 + 氨溴索�。� 參考：《中華醫(yī)院感染學(xué)雜志》2014年13期

【摘要】：目的探討左氧氟沙星聯(lián)合氨溴索治療肺結(jié)核患者肺部感染的臨床效果。方法選取2011年4月-2013年1月肺結(jié)核合并肺部感染患者136例,隨機分為兩組,其中對照組65例、觀察組71例;兩組患者均給予基礎(chǔ)營養(yǎng)治療和常規(guī)抗結(jié)核治療,對照組患者同時給予左氧氟沙星靜脈滴注,觀察組患者給予左氧氟沙星靜脈滴注的同時再給予氨溴索靜脈滴注,對兩組患者的治療效果進行評價,記錄兩組患者痰液病原菌轉(zhuǎn)陰時間和病灶吸收情況;采用SPSS13.0軟件進行統(tǒng)計分析。結(jié)果肺結(jié)核合并肺部感染患者治療顯效率和總有效率觀察組分別為61.97%和92.96%,對照組分別為47.69%和67.69%;觀察組患者痰液病原菌轉(zhuǎn)陰時間為(7.95±2.73)d,對照組為(11.47±3.20)d,觀察組明顯短于對照組;觀察組病灶顯著吸收和總吸收率分別為50.70%和84.51%,對照組分別為27.69%和61.54%,觀察組患者明顯高于對照組,上述比較兩組差異有統(tǒng)計學(xué)意義(P0.05);兩組患者均無嚴重不良反應(yīng)發(fā)生。結(jié)論對肺結(jié)核合并肺部感染患者實施左氧氟沙星沙星聯(lián)合氨溴索治療安全而有效,而且用藥簡單,可以在臨床工作中作為常規(guī)治療方式進行推廣。
[Abstract]:Objective to investigate the clinical effect of levofloxacin combined with ambroxol in the treatment of pulmonary infection in patients with pulmonary tuberculosis. Methods 136 patients with pulmonary tuberculosis complicated with pulmonary infection from April 2011 to January 2013 were randomly divided into two groups: the control group (n = 65) and the observation group (n = 71). The patients in the control group were given levofloxacin intravenous drip at the same time, and the patients in the observation group were given levofloxacin intravenous drip and ambroxol intravenous drip at the same time. The sputum negative time and lesion absorption of sputum were recorded and analyzed by SPSS13.0 software. Results the effective rate and total effective rate were 61.97% and 92.96 in the observation group, 47.69% and 67.69% in the control group, respectively, and the negative time of pathogenic bacteria in sputum was 7.95 鹵2.73 days in the observation group and 11.47 鹵3.20 days in the control group, which was significantly shorter than that in the control group. The significant absorption and total absorption rate were 50.70% and 84.51 in the observation group, 27.69% and 61.54 in the control group, respectively. The patients in the observation group were significantly higher than those in the control group, and the difference between the two groups was statistically significant (P 0.05), and no serious adverse reactions occurred in the two groups. Conclusion levofloxacin combined with ambroxol is safe and effective in the treatment of pulmonary tuberculosis patients with pulmonary infection.
【作者單位】： 英德市人民醫(yī)院感染科;英德市m[m8醫(yī)院功能科;
【基金】：廣東省衛(wèi)生廳重點基金資助項目(GW-2010B-1023)
【分類號】：R521

【參考文獻】

相關(guān)期刊論文 前1條

1 李志惠;張紅漫;劉朋沖;趙杰;馮秀莉;李毅;崔丹;;耐藥肺結(jié)核合并藥物性肝損傷含莫西沙星方案的臨床研究[J];臨床肺科雜志;2010年12期

【共引文獻】

相關(guān)期刊論文 前2條

1 吳知;;莫西沙星治療復(fù)治耐藥肺結(jié)核病的臨床觀察[J];黑龍江醫(yī)藥;2012年01期

2 黃麗貞;雷光遠;雷招寶;;莫西沙星致肝損害16例文獻分析[J];藥物流行病學(xué)雜志;2012年12期

【二級參考文獻】

相關(guān)期刊論文 前4條

1 張英,趙志剛,張杰;莫西沙星——一種新的氟喹諾酮類藥物[J];中國臨床藥理學(xué)雜志;2002年05期

2 畢經(jīng)瑞,邱興屹;左氧氟沙星治療復(fù)治肺結(jié)核療效觀察[J];吉林醫(yī)學(xué);2003年04期

3 許光輝;陳志宇;黃廣軍;;抗結(jié)核藥物誘導(dǎo)肝損傷的臨床分析[J];臨床肺科雜志;2009年06期

4 馬s，

本文編號：1977112